Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator's model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. Cydan was launched in 2013 by a management team with extensive drug development and commercialization experience and with financing from leading investors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/11/13 | $16,000,000 |
Alexandria Real Estate Equities Pfizer Venture Investments | undisclosed | |
| 10/01/13 | $10,000,000 |
Alexandria Real Estate Equities Bay City Capital Lundbeckfond Ventures | undisclosed | |
| 10/17/17 | $34,000,000 |
Alexandria Venture Investments Longitude Capital Lundbeckfond Ventures Pfizer Venture Investments | undisclosed |
